Triamcinolone
- Generic Name
- Triamcinolone
- Brand Names
- Allernaze, Aristocort, Aristocort R, Juulissa Pharmapak, Kenalog, Kourzeq, Marcaine, Nasacort, Oracort, Oralone, Pediaderm Ta, Triaderm, Trianex, Triderm, Triesence, Triloan Suik, Tritocin, Viaderm Kc, Xipere, Zilretta
- Drug Type
- Small Molecule
- Chemical Formula
- C21H27FO6
- CAS Number
- 124-94-7
- Unique Ingredient Identifier
- 1ZK20VI6TY
- Background
Triamcinolone is a corticosteroid used to treat various inflammatory conditions in the body from allergic rhinitis to acute exacerbations of multiple sclerosis. Triamcinolone can be used as a one time adjunct treatment of osteoarthritic knee pain, or first line as a topical treatment of corticosteroid responsive dermatoses. Triamcinolone is more commonly see...
- Indication
肾上腺皮质激素类药。主要用于过敏性与自身免疫性炎症性疾病。由于本品潴钠作用较弱，故一般不用作肾上腺皮质功能减退的替代治疗。
- Associated Conditions
- Acne, Acne Vulgaris, Acute Gouty Arthritis, Allergic Contact Dermatitis, Allergic Rhinitis (AR), Allergic Skin Reaction, Alopecia Areata (AA), Ankylosing Spondylitis (AS), Aphthous Stomatitis, Asthma, Atopic Dermatitis, Autoimmune Hemolytic Anemia, Berylliosis, Bullous dermatitis herpetiformis, Chronic Eczema, Chronic Inflammatory Skin Diseases, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Contact Dermatitis, Crohn's Disease (CD), Dental Cavity, Dermatitis, Dermatomyositis (DM), Diaper Rash, Discoid Lupus Erythematosus (DLE), Edema of the cerebrum, Epicondylitis, Erythroderma, Fungal Infections, Fungal infectious disorders of the Beard, Fungal skin infection, Gingivitis, Haemorrhoids, Hemangiomas, Hypercalcemia, Inflammation of Mouth, Intertrigo, Itching of the Anus, Itching of the External Genitalia, Itching of the Foot, Itching of the genitals, Itching of the hand, Juvenile Idiopathic Arthritis (JIA), Keloids Scars, Leukemias, Lichen Planus (LP), Lichen simplex chronicus, Lymphoma, Macular Edema, Mycosis Fungoides (MF), Mycotic Eczema, Necrobiosis lipoidica diabeticorum, Neurodermatitis, Nummular Dermatitis, Ocular Inflammation, Ophthalmia, Sympathetic, Oral Erosive Lichen Planus, Otitis Externa, Pemphigus, Pericarditis, Polymyositis, Postherpetic Neuralgia, Primary adrenocortical insufficiency, Proteinuria, Psoriasis Vulgaris (Plaque Psoriasis), Psoriatic Arthritis, Psoriatic plaque, Pure Red Cell Aplasia, Purulent Wounds, Pyoderma caused by susceptible bacteria, Regional Enteritis, Rheumatoid Arthritis, Ringworm Folliculitis, Seborrheic Dermatitis, Seborrheic Dermatitis, Eczematous, Secondary Impetiginization, Secondary adrenocortical insufficiency, Secondary thrombocytopenia, Serum Sickness, Skin chapped, Stomatitis, Denture, Synovitis, Systemic Lupus Erythematosus, Temporal Arteritis, Tinea Corporis, Transfusion Reactions, Trichinosis, Tuberculosis (TB), Ulcerative Colitis, Urticaria, Uveitis, Wound Infections, Acute Bursitis, Acute Multiple sclerosis, Acute Rheumatic heart disease, unspecified, Acute Tenosynovitis, Corticosteroid-responsive dermatoses, Cutaneous candidiasis, Cystic tumour of the ganglia, Exfoliative erythroderma, Granuloma annulare lesions, Idiopathic eosinophilic pneumonias, Non-suppurative Thyroiditis, Oral infections, Oral lesions, Severe Erythema multiforme, Subacute Dermatitis, Eczematous, Symptomatic Sarcoidosis, Ulceration of the mouth, Ulcerative stomatitis
- Associated Therapies
- -
Clearside Biomedical Showcases Breakthrough SCS Technology After 10000+ Successful Injections
Clearside Biomedical showcased suprachoroidal delivery tech and pipeline at medical meetings in Asia, Europe, and the U.S., notably at the 17th APVRS Congress in Singapore with ODYSSEY topline results, XIPERE® real-world data, and four posters. Three fully-attended SCS Microinjector® demo sessions were held. Over 10,000 injections have been performed, establishing Clearside as a leader in suprachoroidal space delivery.
Clearside Biomedical Extends Global Footprint with Numerous
Clearside Biomedical presented suprachoroidal delivery tech and pipeline data at APVRS, OIS, and FLORetina, highlighting ODYSSEY wet AMD results and XIPERE real-world data.
Clearside Biomedical advances CLS-AX into Phase 3 trials
Clearside Biomedical advances CLS-AX, its lead drug candidate for wet AMD, into Phase 3 clinical development following positive Phase 2b ODYSSEY trial results. CLS-AX, administered via the SCS Microinjector®, showed an 84% reduction in injection frequency and extended treatment intervals, potentially offering a longer-acting treatment for retinal diseases. The company's financial stability and recent leadership changes support ongoing operations and clinical advancements.
Harrow relaunches triamcinolone acetonide injectable suspension
Harrow relaunches Triesence, a preservative-free triamcinolone acetonide injectable suspension for vitrectomy and ocular inflammation unresponsive to topical corticosteroids. The relaunch addresses a 5-year FDA Drug Shortage List absence, providing safer, more effective treatment for eyecare professionals and patients.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath